1. Home
  2. ORIC vs EU Comparison

ORIC vs EU Comparison

Compare ORIC & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ORIC
  • EU
  • Stock Information
  • Founded
  • ORIC 2014
  • EU 2009
  • Country
  • ORIC United States
  • EU United States
  • Employees
  • ORIC N/A
  • EU N/A
  • Industry
  • ORIC Biotechnology: Pharmaceutical Preparations
  • EU Other Metals and Minerals
  • Sector
  • ORIC Health Care
  • EU Basic Materials
  • Exchange
  • ORIC Nasdaq
  • EU Nasdaq
  • Market Cap
  • ORIC 362.9M
  • EU N/A
  • IPO Year
  • ORIC 2020
  • EU N/A
  • Fundamental
  • Price
  • ORIC $10.65
  • EU $2.89
  • Analyst Decision
  • ORIC Strong Buy
  • EU Strong Buy
  • Analyst Count
  • ORIC 8
  • EU 1
  • Target Price
  • ORIC $18.83
  • EU $2.75
  • AVG Volume (30 Days)
  • ORIC 1.0M
  • EU 3.7M
  • Earning Date
  • ORIC 08-11-2025
  • EU 08-13-2025
  • Dividend Yield
  • ORIC N/A
  • EU N/A
  • EPS Growth
  • ORIC N/A
  • EU N/A
  • EPS
  • ORIC N/A
  • EU N/A
  • Revenue
  • ORIC N/A
  • EU $46,179,000.00
  • Revenue This Year
  • ORIC N/A
  • EU $27.46
  • Revenue Next Year
  • ORIC N/A
  • EU $140.12
  • P/E Ratio
  • ORIC N/A
  • EU N/A
  • Revenue Growth
  • ORIC N/A
  • EU N/A
  • 52 Week Low
  • ORIC $3.90
  • EU $1.01
  • 52 Week High
  • ORIC $14.67
  • EU $4.44
  • Technical
  • Relative Strength Index (RSI)
  • ORIC 68.45
  • EU 69.45
  • Support Level
  • ORIC $9.80
  • EU $2.25
  • Resistance Level
  • ORIC $11.19
  • EU $2.93
  • Average True Range (ATR)
  • ORIC 0.60
  • EU 0.19
  • MACD
  • ORIC -0.05
  • EU 0.03
  • Stochastic Oscillator
  • ORIC 76.92
  • EU 90.14

About ORIC Oric Pharmaceuticals Inc.

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Share on Social Networks: